https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37519 Wed 27 Jan 2021 16:48:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53423 Wed 17 Apr 2024 14:39:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27199 Wed 11 Apr 2018 17:09:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19222 Wed 11 Apr 2018 16:57:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27229 Wed 11 Apr 2018 15:03:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31127 Wed 11 Apr 2018 11:44:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48583 Tue 21 Mar 2023 18:09:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43470 4 months (75% mepolizumab; 25% omalizumab, and 25% macrolide) were recruited. Qualitative semi structured interviews were conducted, with interviews thematically analysed. Results: Participants’ mean (SD) age was 59.5 (15.3) years, and 50% were male. Participants reported 4.5 (2.3) exacerbations in the past year. Asthma Control Questionnaire score was 2.0 (1.4). The monoclonal add-on therapies had been prescribed for a median (IQR) of 12.5 (7.0, 24.0) months. Experience was captured in four emergent themes: “Life is just easier” provided an overall message that the add-on therapy made the participants’ life easier in terms of increasing participation, levelling out symptoms, providing more energy and reducing healthcare use. “Prednisone: A necessary evil” was discussed, particularly in terms of dose and dependence and damaging side effects. The theme “worry and hope for the future” referenced treatment non-response or cessation of effect which was discussed by some participants. Finally, “holistic care” was centred on the sentiment that the participant’s asthma management and overall health were not related to one aspect or medication alone. Conclusion: Patients with severe asthma experience vast improvements in quality-of-life and life participation with add-on therapies, but there remains a significant burden related to oral corticosteroids and incomplete treatment responses. Addressing this residual burden is an important area for future research.]]> Tue 20 Sep 2022 10:13:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52219 Thu 05 Oct 2023 10:22:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16870 Sat 24 Mar 2018 07:54:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5318 Sat 24 Mar 2018 07:45:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26614 Sat 24 Mar 2018 07:34:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32606 Mon 25 Jun 2018 12:15:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48510 Care4myHeart. Objective: This research aimed to determine patient experiences of using the app to self-manage heart failure. Methods: Patients with heart failure used the app for 14 days on their own smart device in a home setting, following which a mixed-methods evaluation was performed. Eight patients were recruited, of whom six completed the Mobile Application Rating Scale and attended an interview. Results: The overall app quality score was “acceptable” with 3.53 of 5 points, with the aesthetics (3.83/5) and information (3.78/5) subscales scoring the highest. The lowest mean score was in the app-specific subscale representing the perceived impact on health behavior change (2.53/5). Frequently used features were weight and fluid restriction tracking, with graphical representation of data particularly beneficial for improved self-awareness and ongoing learning. The use of technology for self-management will fundamentally differ from current practices and require a change in daily routines. However, app use was correlated with potential utility for daily management of illness with benefits of accurate recording and review of personal health data and as a communication tool for doctors to assist with care planning, as all medical information is available in one place. Technical considerations included participants’ attitudes toward technology, functionality and data entry issues, and relatively minor suggested changes. Conclusions: The findings from this usability study suggest that a significant barrier to adoption is the lack of integration of technology into everyday life in the context of already established disease self-management routines. Future studies should explore the barriers to adoption and sustainability of consumer mobile health interventions for chronic conditions, particularly whether introducing such apps is more beneficial at the commencement of a self-management regimen.]]> Mon 20 Mar 2023 16:25:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39985 Fri 22 Jul 2022 13:00:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43396 Fri 16 Sep 2022 09:58:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54859 Fri 15 Mar 2024 17:15:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49364 Fri 12 May 2023 12:42:06 AEST ]]>